Bacillus coagulans efficiency in treating antibiotic-associated diarrhea in immunodeficiency mice
Keywords:
Bacillus coagulans, pharmacology, diarrhea, immunodeficiencyAbstract
Introduction. One of the most promising probiotic including spore-forming microorganisms is a lactobacilli Bacillus coagulans (BC). In the spore form, it is resistant to technological processes and storage, it does not collapse under the influence of gastric juice and bile. After getting into the duodenum, the BC spores can germinate into vegetative bacteria in the human intestine and exert their probiotic effects. BC is not a part of dietary supplements. Recently, many drugs with proven clinical efficiency, based on BC, in the global pharmaceutical market are present. Based on the BC, the drug Laktovit Forte’s influence on the digestive disorders and intestinal dysbiosis caused by streptomycin chronic administration in immunodeficiency mice was investigated in this study. Materials and methods. Work carried out on white outbred mice weighing 20-22 g to simulate digestion disorders characterized by diarrhea in mice for 9 days through streptomycin administered intragastrically at a dose of 2 g / kg of body weight. Disorders in the immune status were modeled by a single subcutaneous injection of cyclophosphamide at a dose of 250 mcg / kg. A Bacillus coagulans from Laktovit Forte was administered to the animals of experimental groups intragastrically at a dose of 46 mg / kg. Comparison drugs were capsules containing Lactobacillus acidophilus (LA-5) and Bifidobacterium animalis subsp. lactis (BB-12). Comparison drugs were also administered intragastrically at a dose of 42 mg / kg. Both drugs were administered beginning from day 6 after antibiotic was started to be administered, the treatment duration was for 7 days. Animals were randomized into groups by 12 animals each: 1 - intact control; 2 - control disease (only streptomycin administered); 3 - pathology with immunosuppression (both streptomycin and cyclophosphamide administered); 4 - streptomycin + Laktovit Forte; 5 - pathology immunosuppression + Laktovit Forte; 6 - streptomycin + reference drug; 5 - pathology immunosuppression + reference drug. Results and discussion. Laktovit Forte (BC) showed pronounced Antidiarrheal effect - the effect was 75%, and in immunodeficiency conditions only 50%. The antidiarrheal effect of the drug based on comparison lactobacilli was 60% in both groups. Similar trends were observed in level of intestinal motility. The Laktovit Forte decreased high intestinal motility during pathology at 61%; in immunosuppression conditions - only 54%. Comparing the drug produced a less pronounced effect, but similar in the groups with and without immunosuppression - respectively 44.5 and 45.9%. BC effects differently under immunosuppressant conditions and without; indicating the importance of immune component in the mechanism of its action in antibiotic-associated diarrhea. The drugs based on comparison bacteria have less pronounced effect, indicating that its probiotic effects and the absence of immune system direct stimulation. The Laktovit Forte is also more effective in preventing body weight loss in animal than comparison drug on the background of the development pathology. For all studies indicates Laktovit Forte was significantly more effective than the drug on the other lactobacillus. Conclusion. Bacillus coagulans from Laktovit Forte provided antidiarrheal effect not only due to the antagonistic probiotic action, but also due to direct stimulation of the immune system.
References
Baryshnikov N.V. Cindroms of bacterial overgrowth (dysbiosis) in the small intestine and colon dysbiosis/ N.V. Baryshnikov, E.I. Tkachenko, Y.P. Assumption // Herald pancreatology Club. - 2009. - № 1 (2). - P. 86.-90.
Hawrelak J.A. The causes of intestinal dysbiosis: a review/ J.A. Hawrelak, S.P. Myers // Altern Med Rev. – 2004. – 9, №2. – Р. 180-197.
Sullivan A. Effect of antimicrobial agents on the ecological balance of human microflora/ A. Sullivan, C. Edlund, C.E. Nord // Lancet Infect.Dis.– 2001.– Vol.1.– N2.– P.101–114.
McFarland L.V. Risk factor for antibiotic–associated diarrhea/ L.V. McFarland // Ann.Med.Intern. (Paris).– 1998.– Vol.149.– N.5.– P.261–266.
Chernin V.V. New aspects of the physiology of the human symbiotic digestion/ V.V. Chernin, A.I. Parfenov, V. M. Bondarenko // Verhnevolzhskiy med. Zh. - 2014 - Vol.12, Issue 1. - P. 18-23.
Simren M. Intestinal microbiota in functional bowel disorders: A Rome foundation report/ M. Simren, G. Barbara, H.J. Flint et al. // Gut. – 2013. – 62. – P. 159–176.
Fuller R. Probiotics and prebiotics: microflora management for improved gut health/ R. Fuller, G. R. Gibson // Clin. Microbiol. and Infect. – 1998. – 4. – P. 477–480.
Tkach S.M. Intestinal microbiota and functional bowel disease / S.M. Tkach, K.S. Tufts, A.K. Sizenko, Y.G. Kuzenko // Suchasna Gastroenterol. - 2014. - №1 (75). - P. 118-129.
Gibson G.R. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics/ G.R. Gibson, M. B. Roberfroid // J. Nutr. – 1995. – 125. – P. 1401–1412.
Sanders M. E., Sporeformers as Human Probiotics: Bacillus, Sporolactobacillus, and Brevibacillus/ M.E. Sanders, L. Morelli, T.A. Tompkins // Compr. Rev. Food Sci. and Food Safety. – 2003. – 2. – P. 101–110.
Hong H.A. The use of bacterial spore formers as probiotics/ H.A. Hong, L.H. Duc, S.M. Cutting // FEMS Microbiol. Rev. – 2005. – 29, №4. – P. 813–835.
Casula G., Bacillus probiotics: spore germination in the gastrointestinal tract/ G. Casula , S.M. Cutting // Appl Environ Microbiol. – 2002. – 68, №5. – Р. 2344-2352.
Adami A. Biomass production, preservation and characteristics of a strain of Bacillus coagulans as probiotic/ A. Adami, V. Cavazzoni// Microbiologie- Aliments- Nutrition. – 1993. – 11. – Р. 93-100.
Kovalenko V.N. Experimental study of potential toxic effects of drugs/ V.N. Kovalenko, O.V. Stefanov, Y.M. Maximov, I.M.Trachtenberg //. Guidelines. - Kyiv, 2001. - P. 74 - 98.
Kozhemyakin Yu.M. Scientific and practical advice on keeping laboratory animals and working with them. / Yu.M. Kozhemyakin, AS Khromov, MA Filonenko, GA Sayfetdinova.//-K .: Avicenna, 2002. - 156 p.
Bioethics examination pre-clinical and other research performed in animals / Guidelines, Kyiv, 2006. - 26 p.
Maslova N.F. Streptomycin model inhibition of digestive hydrolases/ Maslova N.F., Bomko T.V., Kramarenko A.A.// - IV Eng. Biochem. Congress: abstracts. ext., ch.II.- Kyiv, 1992.- p.170.
Pokhyl S.I. The biological method for detecting pathogens transmissible bacterial infections: anaplasmosis, bartonelliosis, erlihiosis / S.I. Pokhyl, E.N. Timchenko, N.A. Chygyryns'ka, L.V. Kylypko etc .// Ukraine patent number 81049. Posted 06.25.2013, Bull. №13.
Experimental (preclinical) study of new drugs with antidiarrheal action. Guidelines. - Kyiv, 2001. - 31 p.
Lapach S.N. Statistical methods in biological studies using Excel/ S.N. Lapach, A.V. Chubenko, P.N. Babich // - K .: Morion. - 2000. - 320 p.
Borovikov V. STATISTICA/ V. Borovikov // Art on a computer analysis of the data: For professionals. 2nd izd.- SPb .: Peter, 2003.- 688 p.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2020 Annals of Mechnikov's Institute
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
